Author

Juntao Xu

Primary ORCID profile (0000-0002-6361-2501 · 1 paper)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Juntao XuiD1 paper · Northwest A&F University

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Genetic & Genomic Medicine· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:whole-exome sequencing· 2 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1 Approach:machine learning (classical)· 1 Approach:statistical model· 1 Research Focus:variant effect prediction· 1

Frequent Co-Authors

Chunming ZhangiD· 2 shared Guangming TaniD· 2 shared Yanhui FaniD· 2 shared Chunli ZhangiD· 1 shared Ciqiu Yang· 1 shared Dongming Zhang· 1 shared Gang NiuiD· 1 shared Gang Niu· 1 shared

Activity by Year

2019-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersGenetic & Genomic Medicine

Chunming ZhangORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Genetic & Genomic MedicinemedRxivPreprintOct 5, 2026

Prediction of ROR1 and CAV1 expression from whole-exome sequencing of tumor tissue and plasma cfDNA to infer the efficacy of B013 plus nab-paclitaxel in triple-negative breast cancer

Min Jiang, Dongming Zhang, Yi-Ching Hsueh…·Gang Niu

The paper predicts ROR1 and CAV1 expression from whole-exome sequencing data to assess response to B013 plus nab-paclitaxel in triple-negative breast cancer, showing agreement with observed responses in 9 out of 10 patients.

DOI 10.64898/2026.09.30.26364376

humanwhole-exome sequencing

𝕏 PostBluesky

Cancer BiologybioRxivPreprintFeb 26, 2019

Rare non-synonymous germline mutations systematically define the risk of triple negative breast cancer

Mei Yang, Yanhui Fan, Zhi-Yong Wu…·Kun Wang

This paper identifies rare germline mutations associated with triple-negative breast cancer risk using a machine learning approach and shows improved risk prediction compared to existing methods.

DOI 10.1101/302398

humanwhole-exome sequencing

𝕏 PostBluesky